Free tool
FAERS Monitor: Gazyva
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125486 or its brand name (Gazyva, Obinutuzumab). Reports on generic versions are filed under their own applications.
Reports
16,929
Serious
14,235
84% of reports
Hospitalization
6,290
Death reported
2,206
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use1,999
- neutropenia1,407
- covid-191,094
- febrile neutropenia1,049
- pyrexia1,027
- thrombocytopenia963
- disease progression961
- infusion related reaction882
- pneumonia805
- anaemia737
- infection625
- atrial fibrillation606
- death557
- cytokine release syndrome547
- myelosuppression547
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 2 |
| 2012 | 19 |
| 2013 | 122 |
| 2014 | 410 |
| 2015 | 375 |
| 2016 | 689 |
| 2017 | 850 |
| 2018 | 1,074 |
| 2019 | 950 |
| 2020 | 1,195 |
| 2021 | 1,177 |
| 2022 | 2,314 |
| 2023 | 2,103 |
| 2024 | 2,473 |
| 2025 | 1,689 |
| 2026 | 1,487 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,230 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cytokine release syndromeSignal | 547 | 34.8 | 32.0 | 17,453 |
| febrile neutropeniaSignal | 1,049 | 19.9 | 18.8 | 18,621 |
| myelosuppressionSignal | 547 | 19.1 | 17.6 | 9,262 |
| infusion related reactionSignal | 882 | 16.7 | 15.7 | 12,906 |
| neutropeniaSignal | 1,407 | 13.0 | 12.3 | 15,485 |
| thrombocytopeniaSignal | 963 | 10.8 | 10.1 | 8,510 |
| disease progressionSignal | 961 | 10.2 | 9.6 | 7,912 |
| covid-19Signal | 1,094 | 7.8 | 7.4 | 6,481 |
| atrial fibrillationSignal | 606 | 7.8 | 7.2 | 3,564 |
| infectionSignal | 625 | 5.4 | 5.0 | 2,232 |
| anaemiaSignal | 737 | 4.8 | 4.5 | 2,236 |
| pyrexiaSignal | 1,027 | 3.7 | 3.5 | 2,044 |
| pneumoniaSignal | 805 | 3.1 | 2.9 | 1,154 |
| off label useSignal | 1,999 | 2.8 | 2.7 | 2,480 |
| death | 557 | 0.8 | 0.7 | 28 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.